Enrolling By InvitationNot applicableNCT07838519
Official study title

Personalizing Veterans' Lung Cancer Screening and Diagnosis

Study summary

Lung cancer screening with low-dose chest computed tomography (CT) is currently recommended for high-risk individuals who are 50 to 80 years old, have smoked cigarettes for at least 20 pack-years, and currently smoke or quit smoking within the past 15 years. In a prospective cohort at Nashville, Denver, Louisville, Chicago, Kansas City, Salisbury and Seattle Veteran Affairs medical centers, the investigators will evaluate the detection of lung cancer using an expanded screening eligibility criteria based on Veterans' personal and service-related exposures compared to standard of care criteria. Screening a larger population will increase the number of lung nodules needing clinical management and these nodules may or may not be cancer. In a population of Veterans with positive screenings at Nashville, the investigators will also validate a combination biomarker-based approach to manage screen-detected lung nodules to reduce time to lung cancer diagnosis and use of invasive procedures. This study will also convene a Veteran Community Advisory Board and interview Veterans to better understand their thoughts about lung cancer screening and preferences for outreach and engagement.

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedLow-dose computed tomography

The study team can explain what participation involves.

Who it may be forLung Cancer Screening · Military Service-related Environmental and Occupational Exposures

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Enrolling By Invitation

Participation is limited to people invited by the study team.

What kind of study?Not applicable

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?VA Office of Research and Development

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
VA Office of Research and Development
Interventions being studied
Procedure: Low-dose computed tomography
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Date of birth and sex recorded 2. Active user of VA (at least 1 primary care encounter in prior 2 years) at Nashville, Denver, Louisville, Chicago Jesse Brown, Kansas City, Salisbury or Seattle VAMC 3. Tobacco Use: Self-reported tobacco use of at least 100 cigarettes in lifetime 4. Additional Risk Factor 1. Self-reported history of military service exposure: direct contact with asbestos- containing material, agent orange, ionizing radiation or burn pit 2. Chronic obstructive pulmonary disease (COPD) defined as one of the two definitions below: 1.Forced expiratory volume during the first second/forced vital capacity (FEV1/ FVC) ratio of below 70% predicted 2.FEV1/FVC greater than 70% predicted or pulmonary function test (PFT) unavailable plus respiratory symptoms (chronic cough, sputum production, shortness of breath, chest tightness, wheezing) plus any one of the following functional abnormalities on PFTs or structural abnormalities on imaging: 1. Functional abnormalities on PFTs: I.FEV1 below the lower limit of normal II.Gas trapping defined as residual volume greater than upper limit of normal III.Hyperinflation defined as two out of three lung volumes (total lung capacity, functional residual capacity, residual volume) that are greater than the upper limit of normal IV.Reduced diffusion capacity of the lungs for carbon monoxide (DLCO) defined as DLCO lower than the lower limit of normal V.Rapid FEV1 decline defined as greater than 60ml/year or greater than or equal to 15% decline in FEV1 2. Structural abnormalities on imaging: I.Emphysema II.Air trapping/mosaicism 3. Self-reported prior history of tobacco-related cancer (oral cavity and pharynx, esophagus, stomach, colorectal, liver and intrahepatic bile duct, pancreas, larynx, lung and bronchus, cervix uteri, kidney and renal pelvis, urinary bladder, and acute non-lymphocytic leukemia) and without evidence of disease for at least 5 years based on chart review 4. Self-reported family history of primary lung cancer in a first degree relative 5.No

Reasons someone may not be able to joinExclusion criteria

at study screening

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Rocky Mountain Regional VA Medical Center, Aurora, COAurora, Colorado
  • Jesse Brown VA Medical Center, Chicago, ILChicago, Illinois
  • Robley Rex VA Medical Center, Louisville, KYLouisville, Kentucky
  • Kansas City VA Medical Center, Kansas City, MOKansas City, Missouri
  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NCSalisbury, North Carolina
  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TNNashville, Tennessee
  • VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 24, 2026. Always confirm current availability with the study team.

View original record ↗